Lawrence Steinman Pasithea Therapeutics Corp. (KTTA) insider trading activity

Lawrence Steinman is Director of Pasithea Therapeutics Corp.. Currently has a direct ownership of 1.33 Million shares of KTTA, which is worth approximately $4.99 Million. The most recent transaction as insider was on Jun 02, 2023, when has been sold 30,000 shares (Common Stock) at a price of $0.43 per share, resulting in proceeds of $12,900. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 1.33M

0% 3M change

0% 12M change

Total Value Held $4.99 Million

LAWRENCE STEINMAN Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jun 02 2023	BUY Open market or private purchase	$12,900 $0.43 p/Share	30,000 Added 2.21%	1,327,174 Common Stock
Nov 28 2022	BUY Grant, award, or other acquisition	$4,900 $0.98 p/Share	5,000 Added 0.39%	1,287,174 Common Stock
Nov 22 2022	BUY Grant, award, or other acquisition	$4,950 $0.99 p/Share	5,000 Added 0.39%	1,282,174 Common Stock
Oct 26 2022	BUY Grant, award, or other acquisition	$5,500 $1.1 p/Share	5,000 Added 0.39%	1,277,174 Common Stock
Oct 17 2022	BUY Grant, award, or other acquisition	$11,400 $1.14 p/Share	10,000 Added 0.78%	1,272,174 Common Stock
Jun 29 2022	BUY Grant, award, or other acquisition	$5,000 $1.0 p/Share	5,000 Added 0.39%	1,272,174 Common Stock
Jun 28 2022	BUY Grant, award, or other acquisition	$5,100 $1.02 p/Share	5,000 Added 0.39%	1,267,174 Common Stock
Jun 27 2022	BUY Grant, award, or other acquisition	$5,000 $1.0 p/Share	5,000 Added 0.39%	1,262,174 Common Stock
Jun 23 2022	BUY Grant, award, or other acquisition	$5,000 $1.0 p/Share	5,000 Added 0.4%	1,257,174 Common Stock
Jun 21 2022	BUY Grant, award, or other acquisition	-	652,174 Added 34.25%	1,252,174 Common Stock

Also insider at

ATNF

180 Life Sciences Corp. Healthcare

Director

BCAB

BioAtla, Inc. Healthcare